RxDoctor Payments Data

Ryan Bellaw, PA

Physician Assistant · Mount Pleasant, TXNPI 1215065917

Payments from drug & device makers

$590in general payments, 2019–2025

Across 31 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$77
  • Novo Nordisk$61
  • Abbott$59
  • Phathom Pharmaceuticals, Inc.$57
  • AbbVie$52
  • Lilly USA, LLC$36
  • plus $248 from 13 others

What the payments were for

  • Food & beverage$590100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$590 in reported general payments places this provider in the 55th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$3,163
Medicare patients
57
Services billed
193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$93,658
TrulicityDulaglutide49$61,817
JardianceEmpagliflozin78$52,182
CreonLipase/Protease/Amylase16$41,969
FarxigaDapagliflozin Propanediol31$30,419
EliquisApixaban42$24,584
JanuviaSitagliptin Phosphate30$21,323
LinzessLinaclotide16$11,241
Tresiba Flextouch U-100Insulin Degludec15$9,159
MyrbetriqMirabegron16$8,404
SymbicortBudesonide/Formoterol Fumarate30$7,713
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$7,075
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$5,064
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$4,388
LantusInsulin Glargine,hum.Rec.Anlog25$3,673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$61$93,65896 claims
Lilly USA, LLCTrulicity$36$61,81749 claims
AbbVieCreon, Linzess, Synthroid$52$54,81549 claims
Boehringer IngelheimJardiance$13$52,18278 claims
AstraZenecaFarxiga, Symbicort$23$38,13261 claims
Sanofi-aventis U.S. LLCLantus$13$3,67325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Mount Pleasant

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →